Cyclosporine monotherapy in pediatric Stevens–Johnson syndrome and toxic epidermal necrolysis: Preserving sepsis indicators while promoting recovery

Stevens–Johnson syndrome and toxic epidermal necrolysis are severe skin reactions seen commonly following exposure to drugs. The quest for the ideal drug to treat these conditions faces significant challenges. There is an absence of head-to-head, comparative, clinical, double-blinded trials comparing the various disease-modifying agents, owing to the rarity and severity of these conditions, along with ethical issues. In such a scenario, gathering data through clinical experiences can provide valuable insights for formulating future guidelines and improving the quality of care. The following case highlights the potential of cyclosporine A to preserve sepsis signs while demonstrating therapeutic efficacy, adding to the growing body of evidence in its favor.